What Hyperfine (HYPR) Said on Its Q3 Earnings Call

Hyperfine (HYPR) reported $13.8M revenue for the first nine months, up 66% YoY, with 36 systems sold. Management maintained its revenue forecast, citing capital equipment deal sizes and visibility. The company discussed its 'land-and-expand' strategy in health systems and progress in contrast imaging studies. Hyperfine also expanded internationally and explored new markets like memory clinics and wellness.

Original reporting
Published Nov 10, 2026, 2:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 2:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Hyperfine (HYPR) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$HYPRBearishMed
01

Why it matters

The earnings release provides fresh data on a micro‑cap medical‑tech firm, offering a modest trading edge for short‑term positioning.

02

Market read

Earnings beat with unchanged outlook creates limited but actionable price movement potential for HYPR.

03

What to watch

Pending FDA clearance for contrast imaging could unlock a larger market later in 2027, not reflected in current guidance.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Hyperfine reported its Q3 results, highlighted strong revenue growth, unit sales, and upcoming regulatory milestones.

Company-level read

Ticker impact

$HYPRBearishHigh confidence
Context

Q3 earnings disclosed $13.8M revenue (+66%) and 36 units sold, with no change to full-year guidance.

Expected impact

likely modest upward pressure as investors digest the strong quarter without new guidance lift

Evidence & confidence

The company delivered a significant revenue increase yet kept its outlook unchanged, suggesting limited upside but confirming execution strength.

Market effects

Positive signal for portable MRI niche; may boost interest in low‑field imaging peers.

European launch of Model 2 could spur regional demand for portable MRI devices.

Limited; primarily affects niche medical‑technology investors.

Counterpoint

Despite revenue growth, the unchanged guidance may signal underlying demand constraints, suggesting a potential pullback.

Key entities

  • Hyperfine, Inc.

    Portable MRI manufacturer (NASDAQ: HYPR).

Related articles

$HYPRMed

Hyperfine, Inc. Reports Third Quarter 2026 Financial Results

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine, Inc. Reports Third Quarter 2026 Financial Results GUILFORD, Conn.--(BUSINESS WIRE)--November 9, 2026--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portab

$HYPRMedAI 9/10

Hyperfine expects Q3 revenue of $6M; shares jump 9%

Hyperfine HYPR reported preliminary Q3 2026 revenue of $6.0M, beating estimates and up 53% sequentially. Shares rose 9% premarket. Net cash burn improved 29% QoQ. Full-year revenue guidance remains $20M-$22M, with cash burn expected to decline 10% YoY. Results will be detailed on Nov 9, 2026.

$HYPRMed

Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to…

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million Preliminary Revenue Represents 53% Sequential Quarterly Growth; Company Reaffirms 2026 Financial Gu

$HYPRMedAI 8/10

Hyperfine (HYPR) Q2 2026 Earnings Call Transcript

Hyperfine (HYPR) reported Q2 2026 revenue of $3.9 million, up 45% year over year, and first-half revenue of $7.8 million, up 62%. Gross margin was 50.7%. Net loss was $9.3 million. Cash was $43.5 million at June 30, 2026. Full-year 2026 guidance: revenue $20-$22 million, gross margin 50%-55%, cash burn $26-$28 million.

$HYPRHigh

Hyperfine, Inc. Reports Second Quarter 2026 Financial Results

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine, Inc. Reports Second Quarter 2026 Financial Results GUILFORD, Connecticut, August 6, 2026 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered